钙网蛋白(CALR)外显子9突变是癌症免疫治疗的有前景靶点
约30%的原发性血小板增多症和原发性骨髓纤维化患者携带CALR外显子9突变。研究建立了针对CALR突变表位的特异性T细胞培养和CD4+ T细胞克隆,这些T细胞能识别自体CALR突变单核细胞和造血干细胞,识别依赖CALR存在且受HLA-DR限制,并可通过脱颗粒对自体CALR突变细胞发挥细胞毒性。结论认为CALR外显子9突变是特异性T细胞的靶点,有望用于肽疫苗接种等癌症免疫治疗。
要点
- CALR外显子9突变见于约30%的原发性血小板增多症和原发性骨髓纤维化患者。
- CALR突变特异性CD4+ T细胞可识别自体CALR突变单核细胞和造血干细胞,识别受HLA-DR限制。
- 该CD4+ T细胞虽表型为CD4+,仍可通过脱颗粒对自体CALR突变细胞发挥细胞毒性。
核心结论
- CALR外显子9突变是特异性T细胞的靶点,有望作为携带CALR外显子9突变患者肽疫苗接种等癌症免疫治疗的靶点。
研究设计与样本
- 本研究建立CALR突变表位特异性T细胞培养及CALR突变特异性CD4+ T细胞克隆,并检测其对自体CALR突变细胞的识别与细胞毒性。
主要发现
- CALR突变特异性T细胞能够识别CALR突变C端的多个表位。
- 通过有限稀释法建立的CALR突变特异性CD4+ T细胞可识别自体CALR突变单核细胞和造血干细胞,且T细胞对靶细胞的识别依赖CALR的存在。
- CALR突变反应受人类白细胞抗原(HLA)-DR限制。
- CALR突变特异性CD4+ T细胞虽为CD4+表型,仍对自体CALR突变细胞具有细胞毒性,该细胞毒性由T细胞脱颗粒介导。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The calreticulin (CALR) exon 9 mutations are found in ∼30% of patients with essential thrombocythemia and primary myelofibrosis. Recently, we reported spontaneous immune responses against the CALR mutations. Here, we describe that CALR-mutant (CALRmut)-specific T cells are able to specifically recognize CALRmut cells. First, we established a T-cell culture specific for a CALRmut epitope. These specific T cells were able to recognize several epitopes in the CALRmut C terminus. Next, we established a CALRmut-specific CD4+ T-cell clone by limiting dilution. These CD4+ T cells recognized autologous CALRmut monocytes and hematopoietic stem cells, and T-cell recognition of target cells was dependent on the presence of CALR. Furthermore, we showed that the CALRmut response was human leukocyte antigen (HLA)-DR restricted. Finally, we demonstrated that the CALRmut-specific CD4+ T cells, despite their phenotype, were cytotoxic to autologous CALRmut cells, and that the cytotoxicity was mediated by degranulation of the T cells. In conclusion, the CALR exon 9 mutations are targets for specific T cells and thus are promising targets for cancer immune therapy such as peptide vaccination in patients harboring CALR exon 9 mutations.
引用
- Holmström MO, Martinenaite E, Ahmad SM, et al. The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy. Leukemia. 2017. PMID: 28676668. doi:10.1038/leu.2017.214
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。